Baudax Bio, Inc. (BXRX)
| Market Cap | 7.58M |
| Revenue (ttm) | 1.30M |
| Net Income (ttm) | -18.09M |
| Shares Out | 6.42M |
| EPS (ttm) | -10.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 104,097 |
| Open | 1.18 |
| Previous Close | 1.11 |
| Day's Range | 1.11 - 1.19 |
| 52-Week Range | 0.94 - 32.87 |
| Beta | 2.24 |
| Analysts | Buy |
| Price Target | 8.16 (+591.5%) |
| Earnings Date | May 5, 2022 |
About BXRX
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intran...
Financial Performance
In 2021, Baudax Bio's revenue was $1.08 million, an increase of 119.07% compared to the previous year's $493,000. Losses were -$19.77 million, -74.02% less than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for BXRX stock is "Buy." The 12-month stock price forecast is 8.16, which is an increase of 591.53% from the latest price.
News
Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders
Annual Meeting to be reconvened on May 18, 2022 Annual Meeting to be reconvened on May 18, 2022
Baudax Bio Reports First Quarter 2022 Financial Results and Business Highlights
ANJESO ® Net Product Revenue Up 113% Compared to Same Period in Prior Year; Sixth Consecutive Quarter of Demand Growth
Baudax Bio to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that it will report first ...
What Makes Baudax Bio, Inc. (BXRX) a New Strong Buy Stock
Baudax Bio, Inc. (BXRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Baudax Bio, Inc. (BXRX) Could be Great Choice for a Bottom Fisher
Baudax Bio, Inc. (BXRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mea...
Baudax Bio Reports 2021 Fourth Quarter and Annual Financial Results
ANJESO End User Demand and Revenue Increases Four Quarters In A Row
Baudax Bio Regains Compliance with NASDAQ Listing Requirements
MALVERN, Pa., March 07, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, announced...
Baudax Bio Announces Pricing of $10.0 Million Public Offering
MALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on commercializing and developing innovative products fo...
Baudax Bio Announces Proposed Public Offering of Securities
MALVERN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on commercializing and developing innovative products fo...
Baudax Bio Announces 1-for-35 Reverse Stock Split
MALVERN, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today annou...
Can These Penny Stocks Climb This Week? 4 To Watch Right Now
Are these penny stocks on your watchlist for next week? The post Can These Penny Stocks Climb This Week?
3 Penny Stocks Under $1 For You List This Week
Penny stocks to watch today The post 3 Penny Stocks Under $1 For You List This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
MALVERN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today annou...
Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care sett...
Baudax Bio Announces $4.2 Million Registered Direct Offering
MALVERN, Pa., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on commercializing and developing innovative products for acute care sett...
Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today annou...
Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents BX-1000, BX-2000 and BX-3000
BX-1000 Completes Dose-Escalation Study; Was Generally Well Tolerated and Rapidly Achieved Muscle Paralysis, Along with Complete Spontaneous Recovery
Baudax Bio Reports Third Quarter 2021 Financial Results and Business Highlights
ANJESO ® Revenue Up 40% in Q3 2021 over Q2 2021 and Up Over 300% in Q3 2021 over Q3 2020
Baudax Bio to Present at the NobleCon Pain Management Investor Forum
MALVERN, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today anno...
Baudax Bio to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
MALVERN, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today ann...
Baudax Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today ann...
5 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...
Do Options Traders Know Something About Baudax Bio (BXRX) Stock We Don't?
Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.
Baudax Bio: Q2 Earnings Insights
Shares of Baudax Bio (NASDAQ:BXRX) rose 0.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 87.79% year over year to ($0.21), which missed the ...
Baudax Bio Reports Second Quarter 2021 Financial Results and Highlights
Total Number of ANJESO ® Vials Sold to End-Users in the Second Quarter 2021 Match Total Vials Sold for the Full Year 2020